89 related articles for article (PubMed ID: 15677349)
21. Evaluation of chemicals as inhibitors of trout cytochrome P450s.
Miranda CL; Henderson MC; Buhler DR
Toxicol Appl Pharmacol; 1998 Feb; 148(2):237-44. PubMed ID: 9473531
[TBL] [Abstract][Full Text] [Related]
22. Mass spectrometry-based quantification of CYP enzymes to establish in vitro/in vivo scaling factors for intestinal and hepatic metabolism in beagle dog.
Heikkinen AT; Friedlein A; Lamerz J; Jakob P; Cutler P; Fowler S; Williamson T; Tolando R; Lave T; Parrott N
Pharm Res; 2012 Jul; 29(7):1832-42. PubMed ID: 22354837
[TBL] [Abstract][Full Text] [Related]
23. Identification of a reversible component in the in vitro inhibition of rat hepatic cytochrome P450 2B1 by parathion.
Murray M; Butler AM
J Pharmacol Exp Ther; 1995 Feb; 272(2):639-44. PubMed ID: 7853177
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenomics of poor drug metabolism in Greyhounds: Cytochrome P450 (CYP) 2B11 genetic variation, breed distribution, and functional characterization.
Martinez SE; Andresen MC; Zhu Z; Papageorgiou I; Court MH
Sci Rep; 2020 Jan; 10(1):69. PubMed ID: 31919457
[TBL] [Abstract][Full Text] [Related]
25. Catalytic selectivity and mechanism-based inactivation of stably expressed and hepatic cytochromes P450 2B4 and 2B5: implications of the cytochrome P450 2B5 polymorphism.
Grimm SW; Dyroff MC; Philpot RM; Halpert JR
Mol Pharmacol; 1994 Dec; 46(6):1090-9. PubMed ID: 7808429
[TBL] [Abstract][Full Text] [Related]
26. Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes.
Graham RA; Tyler LO; Krol WL; Silver IS; Webster LO; Clark P; Chen L; Banks T; LeCluyse EL
J Biochem Mol Toxicol; 2006; 20(2):69-78. PubMed ID: 16615094
[TBL] [Abstract][Full Text] [Related]
27. In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes.
Kuroha M; Kuze Y; Shimoda M; Kokue E
Am J Vet Res; 2002 Jun; 63(6):900-5. PubMed ID: 12061540
[TBL] [Abstract][Full Text] [Related]
28. Kinetics and selectivity of mechanism-based inhibition of guinea pig hepatic and pulmonary cytochrome P450 by N-benzyl-1-aminobenzotriazole and N-alpha-methylbenzyl-1-aminobenzotriazole.
Sinal CJ; Bend JR
Drug Metab Dispos; 1996 Sep; 24(9):996-1001. PubMed ID: 8886610
[TBL] [Abstract][Full Text] [Related]
29. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2005 Apr; 313(1):154-64. PubMed ID: 15608076
[TBL] [Abstract][Full Text] [Related]
30. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity.
Tang C; Shou M; Rodrigues AD
Drug Metab Dispos; 2000 May; 28(5):567-72. PubMed ID: 10772636
[TBL] [Abstract][Full Text] [Related]
31. Ordered chimerogenesis applied to CYP2B P450 enzymes.
Lautier T; Urban P; Loeper J; Jezequel L; Pompon D; Truan G
Biochim Biophys Acta; 2016 Jul; 1860(7):1395-403. PubMed ID: 27015760
[TBL] [Abstract][Full Text] [Related]
32. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518
[TBL] [Abstract][Full Text] [Related]
33. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
Atkinson A; Kenny JR; Grime K
Drug Metab Dispos; 2005 Nov; 33(11):1637-47. PubMed ID: 16049126
[TBL] [Abstract][Full Text] [Related]
34. Testosterone hydroxylation in bovine liver: enzyme kinetic and inhibition study.
Pegolo S; Giantin M; Dacasto M; Montesissa C; Capolongo F
Xenobiotica; 2010 Apr; 40(4):255-61. PubMed ID: 20088676
[TBL] [Abstract][Full Text] [Related]
35. Amino acid residues critical for differential inhibition of CYP2B4, CYP2B5, and CYP2B1 by phenylimidazoles.
Spatzenegger M; Wang Q; He YQ; Wester MR; Johnson EF; Halpert JR
Mol Pharmacol; 2001 Mar; 59(3):475-84. PubMed ID: 11179442
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase.
Locuson CW; Ethell BT; Voice M; Lee D; Feenstra KL
Drug Metab Dispos; 2009 Mar; 37(3):457-61. PubMed ID: 19074522
[TBL] [Abstract][Full Text] [Related]
37. Progesterone metabolism in hepatic microsomes. Effect of the cytochrome P-450 inhibitor, ketoconazole, and the NADPH 5 alpha-reductase inhibitor, 4-MA, upon the metabolic profile in human, monkey, dog, and rat.
Swinney DC
Drug Metab Dispos; 1990; 18(6):859-65. PubMed ID: 1981529
[TBL] [Abstract][Full Text] [Related]
38. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs.
Mills BM; Zaya MJ; Walters RR; Feenstra KL; White JA; Gagne J; Locuson CW
Drug Metab Dispos; 2010 Mar; 38(3):396-404. PubMed ID: 20007294
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate.
Kim JY; Baek M; Lee S; Kim SO; Dong MS; Kim BR; Kim DH
Drug Metab Dispos; 2001 Dec; 29(12):1555-60. PubMed ID: 11717174
[TBL] [Abstract][Full Text] [Related]
40. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
